parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in neutrophils	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 192	0.79
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 8103

receipt 8111: CREB5 in dopamine neurons, braak

power: full sample -0.05 (p 0.840, n 18), 95% CI -0.51 to +0.43. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.08 (p 0.741, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.774, n 18). could be the mix.
skeptic: leave-one-out range -0.18 to +0.04, sign flips 4; without severely affected donors -0.05 (p 0.840, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CREB5 in dopamine neurons.

case closed: nothing better to follow up.

receipt 8110: CREB5 in oligodendrocytes, braak

power: full sample +0.31 (p 0.211, n 18), 95% CI -0.18 to +0.68. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.33 (p 0.179, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.30 (p 0.228, n 18). could be the mix.
skeptic: leave-one-out range +0.23 to +0.45, sign flips 0; without severely affected donors +0.31 (p 0.211, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CREB5 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts